Stay Up To Date

Latest News

Latest blogs, press releases, and reports from P4ADNOW.

Latest News | May 15, 2026

The Week in Review in Prescription Drug Pricing: Patent Barriers Delay Generic Ozempic in the U.S., Bipartisan Push Targets Pharmacy-PBM Integration, and Tariff Policy Drives Industry Workarounds – Not Lower Prices

Latest News | May 8, 2026

The Week in Review in Prescription Drug Pricing: P4AD Reaches 40K Patient Stories, White House MFN Savings Estimates Raise Questions, and New Report Highlights Growing Use of Patent Tactics to Delay Competition

Latest News | May 1, 2026

The Week in Review in Prescription Drug Pricing: SCOTUS Examines Skinny Labels, Rx Prices Remain Top Voter Concern, and more

Latest News | Apr 24, 2026

The Week in Review in Prescription Drug Pricing: Regeneron Signs MFN Deal, Pharma Tops Q1 Healthcare Lobbying, Bipartisan Hill Pharma Probe, and more

Latest News | Apr 17, 2026

The Week in Review in Prescription Drug Pricing: Medicare Negotiation Round 3 Drugs and ORPHAN’s Impact, Healthcare Costs Top Worry for Americans, and more

Latest News | Apr 10, 2026

The Week in Review in Prescription Drug Pricing: TrumpRx adds Humira, Pharma Threatens CO’s PDAB, Ubl Out, P4AD Expands, and more

Latest News | Apr 3, 2026

The Week in Review in Prescription Drug Pricing: 100% Tariffs Are Back, Admin Admits MFN Deals Won’t Lower U.S. Prices, Americans Want Generic Options

Latest News | Mar 27, 2026

The Week in Review in Prescription Drug Pricing: New Analysis, FTC Settles Second PBM Case, Merck Acquisitions as Keytruda Patent Cliff Approaches, and more